Reading view
Permanent Telehealth Flexibilities Should Not Be Controversial
(MedPage Today) -- As yet another government shutdown looms, telehealth's uncertainty remains -- and seniors risk paying the price.
While headlines about the last government closure focused on insurance premiums, millions of seniors across the... Exclusive eBook: How AGI Became a Consequential Conspiracy Theory
In this exclusive subscriber-only eBook, you’ll learn about how the idea that machines will be as smart as—or smarter than—humans has hijacked an entire industry.
by Will Douglas Heaven October 30, 2025
Table of Contents:
- How Silicon Valley got AGI-pilled
- The great AGI conspiracy
- How AGI hijacked an industry
- The great AGI conspiracy, concluded
Related Stories:
Access all subscriber-only eBooks:
Molecular features of early- vs. late-onset gastric cancer: a systematic review and meta-analysis
BMC Cancer. 2026 Jan 14. doi: 10.1186/s12885-026-15567-5. Online ahead of print.
ABSTRACT
BACKGROUND: Early-onset gastric cancer (EOGC), diagnosed before age 50, is characterized by distinct clinicopathological features, though its molecular landscape remains poorly defined.
METHODS: A systematic literature search of PubMed, Embase, and Web of Science identified studies comparing molecular characteristics of EOGC and late-onset gastric cancer (LOGC). Meta-analyses assessed differences in The Cancer Genome Atlas (TCGA) molecular subtypes, gene mutations, therapeutic biomarkers, and serum tumor markers. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated; heterogeneity was assessed using the I2 statistic.
RESULTS: EOGC was associated with a higher prevalence of the genomically stable (GS) subtype (OR = 1.71, 95% CI: 1.37-2.12) and a lower prevalence of the chromosomal instability (CIN) subtype (OR = 0.62, 95% CI: 0.50-0.77). CDH1 mutations were more frequent in EOGC (OR = 3.44, 95% CI: 2.85-4.16), while HER2 expression (OR = 0.54, 95% CI: 0.43-0.67), dMMR/MSI-H status (OR = 0.25, 95% CI: 0.12-0.53), and p53 expression (OR = 0.56, 95% CI: 0.39-0.82) were significantly lower. Serum markers including CEA and CA19-9 were also less frequently elevated in EOGC.
CONCLUSION: EOGC represents a biologically distinct subset of gastric cancer with unique genomic and immunological features. These findings support age-specific diagnostic approaches and emphasize the value of multiomic strategies to uncover the mechanisms driving early-onset disease.
PMID:41535782 | DOI:10.1186/s12885-026-15567-5
AI medical diagnostics race intensifies as OpenAI, Google, and Anthropic launch competing healthcare tools
OpenAI, Google, and Anthropic announced specialised medical AI capabilities within days of each other this month, a clustering that suggests competitive pressure rather than coincidental timing. Yet none of the releases are cleared as medical devices, approved for clinical use, or available for direct patient diagnosis—despite marketing language emphasising healthcare transformation.
OpenAI introduced ChatGPT Health on January 7, allowing US users to connect medical records through partnerships with b.well, Apple Health, Function, and MyFitnessPal. Google released MedGemma 1.5 on January 13, expanding its open medical AI model to interpret three-dimensional CT and MRI scans alongside whole-slide histopathology images.
Anthropic followed on January 11 with Claude for Healthcare, offering HIPAA-compliant connectors to CMS coverage databases, ICD-10 coding systems, and the National Provider Identifier Registry.
All three companies are targeting the same workflow pain points—prior authorisation reviews, claims processing, clinical documentation—with similar technical approaches but different go-to-market strategies.
Developer platforms, not diagnostic products
The architectural similarities are notable. Each system uses multimodal large language models fine-tuned on medical literature and clinical datasets. Each emphasises privacy protections and regulatory disclaimers. Each positions itself as supporting rather than replacing clinical judgment.

The differences lie in deployment and access models. OpenAI’s ChatGPT Health operates as a consumer-facing service with a waitlist for ChatGPT Free, Plus, and Pro subscribers outside the EEA, Switzerland, and the UK. Google’s MedGemma 1.5 releases as an open model through its Health AI Developer Foundations program, available for download via Hugging Face or deployment through Google Cloud’s Vertex AI.
Anthropic’s Claude for Healthcare integrates into existing enterprise workflows through Claude for Enterprise, targeting institutional buyers rather than individual consumers. The regulatory positioning is consistent across all three.
OpenAI states explicitly that Health “is not intended for diagnosis or treatment.” Google positions MedGemma as “starting points for developers to evaluate and adapt to their medical use cases.” Anthropic emphasises that outputs “are not intended to directly inform clinical diagnosis, patient management decisions, treatment recommendations, or any other direct clinical practice applications.”

Benchmark performance vs clinical validation
Medical AI benchmark results improved substantially across all three releases, though the gap between test performance and clinical deployment remains significant. Google reports that MedGemma 1.5 achieved 92.3% accuracy on MedAgentBench, Stanford’s medical agent task completion benchmark, compared to 69.6% for the previous Sonnet 3.5 baseline.
The model improved by 14 percentage points on MRI disease classification and 3 percentage points on CT findings in internal testing. Anthropic’s Claude Opus 4.5 scored 61.3% on MedCalc medical calculation accuracy tests with Python code execution enabled, and 92.3% on MedAgentBench.
The company also claims improvements in “honesty evaluations” related to factual hallucinations, though specific metrics were not disclosed.
OpenAI has not published benchmark comparisons for ChatGPT Health specifically, noting instead that “over 230 million people globally ask health and wellness-related questions on ChatGPT every week” based on de-identified analysis of existing usage patterns.
These benchmarks measure performance on curated test datasets, not clinical outcomes in practice. Medical errors can have life-threatening consequences, translating benchmark accuracy to clinical utility more complex than in other AI application domains.
Regulatory pathway remains unclear
The regulatory framework for these medical AI tools remains ambiguous. In the US, the FDA’s oversight depends on intended use. Software that “supports or provides recommendations to a health care professional about prevention, diagnosis, or treatment of a disease” may require premarket review as a medical device. None of the announced tools has FDA clearance.
Liability questions are similarly unresolved. When Banner Health’s CTO Mike Reagin states that the health system was “drawn to Anthropic’s focus on AI safety,” this addresses technology selection criteria, not legal liability frameworks.
If a clinician relies on Claude’s prior authorisation analysis and a patient suffers harm from delayed care, existing case law provides limited guidance on responsibility allocation.
Regulatory approaches vary significantly across markets. While the FDA and Europe’s Medical Device Regulation provide established frameworks for software as a medical device, many APAC regulators have not issued specific guidance on generative AI diagnostic tools.
This regulatory ambiguity affects adoption timelines in markets where healthcare infrastructure gaps might otherwise accelerate implementation—creating a tension between clinical need and regulatory caution.
Administrative workflows, not clinical decisions
Real deployments remain carefully scoped. Novo Nordisk’s Louise Lind Skov, Director of Content Digitalisation, described using Claude for “document and content automation in pharma development,” focused on regulatory submission documents rather than patient diagnosis.
Taiwan’s National Health Insurance Administration applied MedGemma to extract data from 30,000 pathology reports for policy analysis, not treatment decisions.
The pattern suggests institutional adoption is concentrating on administrative workflows where errors are less immediately dangerous—billing, documentation, protocol drafting—rather than direct clinical decision support where medical AI capabilities would have the most dramatic impact on patient outcomes.
Medical AI capabilities are advancing faster than the institutions deploying them can navigate regulatory, liability, and workflow integration complexities. The technology exists. The US$20 monthly subscription provides access to sophisticated medical reasoning tools.
Whether that translates to transformed healthcare delivery depends on questions these coordinated announcements leave unaddressed.
See also: AstraZeneca bets on in-house AI to speed up oncology research
Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events. Click here for more information.
AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.
The post AI medical diagnostics race intensifies as OpenAI, Google, and Anthropic launch competing healthcare tools appeared first on AI News.
ART: Action-based Reasoning Task Benchmarking for Medical AI Agents
Human-AI Co-design for Clinical Prediction Models
PrivacyReasoner: Can LLM Emulate a Human-like Privacy Mind?
Companion Agents: A Table-Information Mining Paradigm for Text-to-SQL
Triples and Knowledge-Infused Embeddings for Clustering and Classification of Scientific Documents
AI Deployment Authorisation: A Global Standard for Machine-Readable Governance of High-Risk Artificial Intelligence
From Symbolic to Natural-Language Relations: Rethinking Knowledge Graph Construction in the Era of Large Language Models
A Marketplace for AI-Generated Adult Content and Deepfakes
Mikasa: A Character-Driven Emotional AI Companion Inspired by Japanese Oshi Culture
Global Benchmark Database
Mitigating Gender Bias via Fostering Exploratory Thinking in LLMs
Exploring the Secondary Risks of Large Language Models
GI-Bench: A Panoramic Benchmark Revealing the Knowledge-Experience Dissociation of Multimodal Large Language Models in Gastrointestinal Endoscopy Against Clinical Standards
Regulatory gray areas of LLM Terms
Large-scale analysis identifies metabolites associated with type 2 diabetes
Nature Medicine, Published online: 15 January 2026; doi:10.1038/s41591-025-04147-y
An integrated analysis of 23,634 individuals identified 235 circulating metabolites associated with future risk of type 2 diabetes and revealed their potential genetic and environmental determinants. These findings provide a foundation for understanding the metabolic landscape underlying type 2 diabetes risk, informing preventative therapies that target specific metabolic pathways.